Hong Kong billionaire Li Ka-shing is expanding support for liver cancer patients through a new medical funding initiative that will help hundreds gain access to advanced treatment at a significantly lower cost.
The Li Ka-shing liver cancer programme was announced on Wednesday by the Li Ka Shing Foundation. Under the plan, the foundation will subsidise liver cancer surgeries for 200 patients in Hong Kong over the next three years.
The initiative aims to make cutting-edge histotripsy treatment more affordable for eligible patients. The procedure normally costs about HK$260,000 for Hong Kong identity card holders. With support from the foundation, selected patients will only need to pay HK$50,000, reducing the financial burden for many families dealing with serious illness.
Three private hospitals in Hong Kong will partner with the foundation to identify and select patients who qualify for the programme. Officials said the hospitals would oversee the referral and evaluation process to ensure patients who can benefit most from the treatment receive support.
Histotripsy is considered one of the newest non-invasive technologies for cancer treatment. The procedure uses high-intensity ultrasound waves to target and destroy tumour tissue without traditional surgery. Instead of cutting into the body, the treatment liquefies cancer cells while limiting damage to surrounding healthy tissue.
Medical experts say the technology may help reduce recovery times and lower the risks often linked to invasive surgical procedures. Each treatment session generally lasts between 15 and 25 minutes and is carried out under general anaesthesia.
The foundation said the programme reflects its broader commitment to improving healthcare access and supporting medical innovation in Hong Kong. The new funding plan is expected to provide hope for liver cancer patients who may otherwise struggle to afford advanced care options.
Liver cancer remains one of the most serious health concerns across Asia, including Hong Kong. Doctors say early diagnosis and access to modern treatment options can significantly improve patient outcomes. However, high treatment costs often create barriers for many patients seeking specialised procedures.
The subsidy programme also highlights the growing role of philanthropy in supporting healthcare services in Hong Kong. Over the years, Li Ka-shing and his charitable foundation have funded major projects in education, healthcare, and scientific research both locally and internationally.
The announcement quickly drew attention from the medical community and patient advocacy groups, many of whom welcomed efforts to make innovative cancer care more accessible. Healthcare professionals noted that newer technologies such as histotripsy could play an increasingly important role in future cancer treatment strategies.
Officials did not immediately release detailed eligibility requirements for applicants. However, the partnering hospitals are expected to provide additional information about the selection process and treatment timeline in the coming months.
The Li Ka-shing liver cancer support programme is expected to begin soon, giving selected patients an opportunity to receive one of the world’s most advanced liver cancer treatments at a fraction of the usual cost.
